Example: Heart Attack

Search clinical trials for: Cyclophosphamide

Total 3806 results

NCT03700450

Recruiting

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

Conditions: Multiple Myeloma
NCT03318016

Active, not recruiting

Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia
NCT01630538

Terminated

Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants

Conditions: Antibody Mediated Rejection
NCT02444091

Unknown status

Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)

Conditions: Chronic Fatigue Syndrome (CFS); Myalgic Encephalomyelitis (ME)
NCT03733587

Completed

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Conditions: Solid Tumor
NCT02139280

Active, not recruiting

Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy

Conditions: Hematologic Malignancies
NCT00501995

Completed

High Dose Cyclophosphamide for Treatment of Scleroderma

Conditions: Scleroderma
NCT02794077

Completed

Cyclophosphamide for Nasopharyngeal Carcinoma

Conditions: Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Undifferentiated Carcinoma
NCT04656262

Recruiting

Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Conditions: Soft Tissue Sarcoma Adult
NCT03936829

Recruiting

Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes

Conditions: Lipodystrophy Acquired; Type1diabetes
NCT04620772

Not yet recruiting

Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis

Conditions: Tuberculosis; Tubercular Meningitis; Arachnoiditis; Tuberculous (Etiology)
NCT03149679

Active, not recruiting

The p53 Colorectal Cancer Trial

Conditions: Colorectal Cancer Metastatic; Colorectal Cancer Stage IV; TP53 Gene Mutation
NCT03200002

Completed

Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis

Conditions: To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients
NCT04243109

Terminated

Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

Conditions: Multiple Myeloma
NCT03187756

Terminated

Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft

Conditions: Hematopoietic Malignancies
NCT01570764

Completed

Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease

Conditions: Systemic Sclerosis; Scleroderma; Interstitial Lung Disease; Lung Fibrosis
NCT03088293

Recruiting

Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)

Conditions: Idiopathic Refractory Scleritis
NCT01229605

Withdrawn

Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer

Conditions: Breast Cancer
NCT02360111

Terminated

GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

Conditions: Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
NCT01740401

Terminated

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

Conditions: Melanoma
NCT01836289

Withdrawn

High-dose Cyclophosphamide for Severe Refractory Crohn Disease

Conditions: Crohn's Disease; Crohn Disease
NCT00743509

Completed

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

Conditions: Osteosarcoma
NCT01462253

Completed

Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults

Conditions: Acute Lymphoblastic Leukemia
NCT04392037

Not yet recruiting

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

Conditions: Multiple Myeloma
NCT02768701

Active, not recruiting

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Conditions: Triple Negative Breast Cancer